Earnings GrowthSI reported results for the first time since the IPO, with net quarterly revenue of $11.0M, reflecting 33% YoY growth, attributed to the accelerating market adoption of its implant systems.
Market PositioningThe company issued FY25 guidance at $42-$44M, demonstrating a growth rate in line with last year's, positioning SI in a strong position to capture market share.
Product DifferentiationSI's InSet Glenoid has seen zero revisions over a 10+ year span in clinical literature.